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ABSTRACT
RNA interference (RNAi)-mediated gene knockdown
is a potent approach for studying gene function.
We have previously reported a plasmid-based,
tamoxifen-inducible gene knockdown system in cul-
turedcellsusingacombinedRNAiand Cre-LoxPsys-
tem.Here,wevalidatethissysteminmouseandshow
that it can be used to suppress the expression of
an endogenous gene (Fgfr2) with high efficiency. We
show that transgenic mice carrying the U6-ploxPneo-
Fgfr2 RNAi construct are normal, displaying Fgfr2
transcripts equivalent to those of wild-type controls,
indicating that the U6 promoter is inactive in vivo
due to the presence of the neo in the promoter. After
excision of the neo by crossing with transgenic mice
that express Cre in the mouse germline, the U6
promoter is activated, leading to over 95% reduction
of Fgfr2 transcripts, and consequently, embryonic
lethality. On the other hand, activation of the U6 pro-
moter using transgenic mice that express Cre in
the progress zone of the limb results in live mice
with malformation of digits of both the forelimbs
and hindlimbs. This method provides a fast, yet effi-
cient way to decipher gene functions in vivo in a
tissue-specific manner.
INTRODUCTION
RNA interference (RNAi) is widely used to target and degrade
speciﬁc mRNA (1). Small interfering RNA or short hairpin
RNA (shRNA)-producing vectors can be transfected in cul-
tured cells, allowing mRNA down-regulation within 24–72 h
(1–5). Plasmids can be stably integrated into host genome and
provide several advantages compared with transfected siRNA
oligos (1–5). In order to provide a controllable RNAi, several
studies have developed inducible regulation of RNAi in mam-
malian cells using either tetracycline or ecdysone-responsive
systems (6–9).
Recently, we have reported a tamoxifen-inducible gene
knockdown system in cultured cells using a combination of
the RNAi and the Cre-LoxP system (3). In this method, we
inserted a neomycin cassette (neo) (10) into the RNA poly-
merase III (U6) promoter to disrupt its activity. Because the
neo is ﬂanked by loxP sites (ploxPneo), it can be excised upon
the Cre-mediated recombination, thus restoring the activity of
the U6promoter (3). Using a tamoxifen-inducible Cre (11), we
have demonstrated that this process indeed works with high
efﬁciency in the suppression of two endogenous genes, ﬁbro-
blast growth factor receptor 2 (Fgfr2) and Survivin, in mouse
embryonic stem (ES) cells (3). The Cre-LoxP system has been
widely utilized for conditional gene knockout in mice (12–14),
and numerous transgenic mouse strains expressing Cre at spe-
ciﬁc tissues/organs have been developed to achieve spatial and
temporal control of gene expression (15). We postulate that
if our U6-ploxPneo-RNAi vector works in mouse, it will even-
tually allow the utilization of a large collection of Cre trans-
genic mice and signiﬁcantly enhance our ability to use RNAi
system to decipher gene function in vivo.
FGFR2 is one of the four high afﬁnity FGF receptors that
mediate the signaling of, at least, 22 FGF ligands (16,17).
Full-length form of FGFR2 contains a hydrophobic leader
sequence, three immunoglobulin (Ig)-like domains, an acidic
box, a transmembrane domain and a divided tyrosine kinase
domain. Many isoforms can be generated through alternative
splicing and internal poly-adenylation. For example, altera-
tions in exons 7–9 that encode the IgIII yield b (FGFR2b) and
c (FGFR2c) isoforms (18,19). It has been shown that missense
mutations of FGFR2 in humans result in at least seven distinct
typesofcraniosynostosissyndromes,primarilyaffectingbones
formed through intramembraneous ossiﬁcation [reviewed in
(17)]. Some patients also display limb abnormalities at birth,
such as short ﬁngers, broad thumbs, bigger toes and/or soft-
tissue syndactyly [reviewed in (20)]. Gene targeting in mouse
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doi:10.1093/nar/gni100revealed that Fgfr2 plays important roles in embryonic devel-
opment and organogenesis. It has been demonstrated that
Fgfr2-null embryos die a few hours after implantation owing
to abnormalities during the implantation process and mal-
formation of the egg cylinder (21). Mutant embryos homozy-
gous for Fgfr2–IgIII domain deletion (Fgfr2
DIII/DIII) die at
embryonic day (E) 10.5–11.5 owing to failure of placenta
formation (22). After rescue of placenta defects with wild-
type tetraploid cells, the Fgfr2
DIII/DIII embryos survive up to
birth; however, they display abnormalities in multiple organs/
tissues (23).
Considering embryonic lethality associated with the loss
of function mutations and the potential critical roles of
FGFR2 in postnatal development (17), we decided to knock-
down this gene in mouse to test the efﬁciency of our Cre-
mediated RNAi strategy. By using two different transgenic
mice that express the Cre in the germline and the progress
zone of the limb, respectively, we have generated mouse
models with dramatically reduced expression of Fgfr2 that
can be used to study functions of this gene in a tissue-
speciﬁc manner.
MATERIALS AND METHODS
Generation of transgenic mice
pBS/U6-ploxPneo-Fgfr2 vector used in this study was
described previously (3). The vector was digested by KpnI
and AﬂIII restriction enzymes and puriﬁed from agarose gel
after electrophoretic migration using the QIAquick Gel
ExtractionKit(Qiagen,Valencia,CA).Thefragment(2745bp)
was resuspended in Tris (1 mM)–EDTA (0.1 mM) buffer and
adjusted to a ﬁnal concentration of 2 ng/ml and injected into
oocytes isolated from FVB/N mice through pronuclear injec-
tion. Offspring from the injection were genotyped using PCR
with the following pair of primers (50-CGAAGTTATCTA-
GAGTCGAC-30 and 50-AAACAAGGCTTTTCTCCAAGG-
30) that ampliﬁes 102 bp from the U6 promoter and the con-
necting neo gene. PCR-positive mice were crossed with wild-
type FVB/N mice to obtain germline transmission. Three
chimeric mice passed the transgene through germline.
Functional analysis of Fgfr2-RNAi transgene
Mice carrying the U6-ploxPneo-Fgfr2-RNAi transgene were
crossed with EIIa-Cre (24) and Ap2-Cre (25) transgenic mice
to assess efﬁciencies of Fgfr2-RNAi transgene. The EIIa-Cre
mice and Ap2-Cre mice were genotyped using the following
pair of primers (Cre-1: 50-CCT GTT TTG CAC GTT CAC
CG-30 and Cre-3: 50-ATG CTT CTG TCC GTT TGC CG-30).
Pregnant EIIa-Cre;U6-ploxPneo-Fgfr2 and Ap2-Cre;U6-
ploxPneo-Fgfr2 mice were killed at different stages of preg-
nancy to check embryonic development. Cre mediated
recombination was veriﬁed by using the following pair of
primers (50-GACGCCGCCATCTCTAGG-30 and 50-AGGCT-
TTTCTCCAAGGGATATT-30). This pair of primers ﬂanks
the ploxPneo in the U6 promoter and ampliﬁes 278 bp after
Cre-mediated recombination. Animals were handled in
accordance with guidelines of the NIDDK Animal Care and
Users Committee.
Whole-mount skeletal preparation
Animals were euthanized by asphyxiation with CO2. After
removing the skin, carcasses were eviscerated, ﬁxed in 95%
ethanol, stained with Alizarin red S and alcian blue, cleared
by KOH treatment, then stored in glycerol as described
previously (26).
PCR, RT–PCR and real-time PCR
RT–PCR was performed on total RNA extracted from
embryos using RNA STAT-60 (Tel-Test, Inc., Friendswood,
TX) and reverse-transcription was performed according to
Ambion’s instructions using ‘Cells-to-cDNA  II kit (Catalog
nos 1722, 1723)’. Two micrograms of RNA were used for
cDNA synthesis using 0.5 mg of oligo(dT)18 primer, 1 mlo f
RNase inhibitor, 1 ml of M-MLV reverse transcriptase and 2 ml
of 10· RT buffer (Ambion) in a ﬁnal volume of 20 ml. The
reaction was carried out for 45 min at 42 C and for 10 min at
95 C and then cooled to 4 C. An aliquot of 1 ml of each RT
reaction product was ampliﬁed to a 24 ml-volume PCR premix,
containing 1 pmol of each primer, 2.5 mM dNTP mix and 1 U
of Taq polymerase. PCR was carried out in a PCR thermal
cycler (Gene Amp PCR Systems 9700). The samples were
heated to 94 C for 2 min, and run through 22–31 cycles
(95 C for 10 s, 60 C for 20 s and 72 C for 30 s) to monitor
linearity of the ampliﬁcation. The PCR was kept in 72 C for
10 min and then stopped at 4 C.
RT–PCR was performed using the following primers:
Fgfr1-F: 50-TTCTGGGCTGTGCTGGTCAC-30 and Fgfr1-R:
50-GCGAACCTTGTAGCCTCCAA-30; Fgfr2-F: 50-AAGGT-
TTACAGCGATGCCCA-30 and Fgfr2-R: 50-ACCACCATG-
CAGGCGATTAA-30; Fgfr3-F: 50-CTAGTGTTCTGCGTG-
GCGGT-30 and Fgfr3-R: 50-TTCTTATCCATTCGCTCC-
GG-30; Fgfr4-F: 50-CTGTTGAGCATCTTTCAGGG-30 and
Fgfr4-R: 50-CGTGGAAGGCCTGTCCATCC-30.
We measured relative gene expression by real-time RT–
PCR as suggested by the manufacturer (ABI PRISM 7500
Realtime System; Applied Biosystems) using the above
primers for Fgfr1, Fgfr3 and Fgfr4. Fgfr2 primers were
described as Fgfr2-Up: 50-TGCCCTACCTCAAGGTTCTG-30;
and Fgfr2-Down: TAGAATTACCCGCCAAGCAC-30.
The following pair of primers for b-actin was used as
control for both RT–PCR and real-time PCR: b-actin-Up:
50-TGCGTGACATCAAAGAGAAG-30; b-actin-Down: 50-
GATGCCACAGGATTCCATA-30.
The following primers were used for genomic real-time
PCR: Neo-U: 50-AGAGGCTATTCGGCTATGACTG-30;
Neo-D: 50-GTGGCCAGCCACGATAGC-30; Fgfr1-U: 50-CC-
CCATCCCATTTCCTTACCT-30; and Fgfr1-D: 50-TTCT-
GGT GTGTCTGAAAACAGCT-30.
For ampliﬁcation of neo gene and neo deletion by genomic
PCR, following pairs of primer were used: Neo-1: 50-AGAG-
GCTATTCGGCTATGACTG-30; Neo-2: 50-TTCGTCCAG-
ATCATCCTGATC-30; Del-1: 50-CGCACAGACTTGTGG-
GAGAA-30; and Del-2: 50-CACAATTACTTTACAGTTAG-
30. Fifty nanograms of DNA was used in the reaction.
Northern blotting
For analysis of the shRNA expression, 20 mg of total RNAs
were resolved in a 15% (wt/vol) polyacrylamide–8 M urea
gel, transferred by electroblotting onto Nytran-N
+ membrane
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by using the auto-crosslink function of a Stratlinker. The
membrane was hybridized overnight to a [g-
32P]labeled DNA
probe corresponding to the 21mer antisense strand ofthe Fgfr2
shRNA (GGCCTCAGCGTTCCTGAGCGA). The hybridiza-
tion (Sigma, Hybridization buffer, PerfectHyb  Plus) and
wash steps were carried out at 37 C. The membrane was then
exposed on a Kodak ﬁlm for overnight before developing the
image.
RESULTS
Expression of U6-Fgfr2 results in embryonic lethality
To study the potential effects of RNAi of Fgfr2 in vivo,
we generated transgenic mice carrying U6-ploxPneo-Fgfr2
(Figure 1A) through pronuclear injection. After breeding
with FVB/N mice, three offspring from the injection passed
the U6-ploxPneo-Fgfr2 transgene through germline. All the
transgenic mice were normal owing to the presence of the neo,
Figure 1. Expression of U6-Fgfr2 resultsin embryoniclethality. (A) Structureof U6-ploxPneo-Fgfr2 transgene beforeand after deletionof ploxPneo.( B) P19U6-
Fgfr2;EIIa-Creand control mice. Abnormal limbs (arrows) were magnified in (C and D). (E and F) E11.5 (E) and E13.5 (F) mutant and control embryos. Wt, wild
type; U6, U6-ploxPneo-Fgfr2; Cre, EIIa-Cre; and U6;Cre, U6-Fgfr2;EIIa-Cre.
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mice with EIIa-Cre transgenic mice that express Cre in
germ cells of the mouse (24). After screening 81 mice
generated from breeding of one founder line (Line A)
with EIIa-Cre transgenic mice, we obtained two live bigenic
(U6-Fgfr2;EIIa-Cre) mice (Table 1, crosses between U6-
ploxPneo-Fgfr2 and EIIa-Cre mice). Both mice appeared
unhealthy at birth and were much smaller than their littermate
control (Figure 1B) with a body weight of about two-third of
their littermates at postnatal day 19 (P19). Both mice also
displayed abnormal limbs (Figure 1C and D). Screening of
40 offspring from other two founder lines failed to obtain live
U6-Fgfr2;EIIa-Cre mice at birth, suggesting that they were
also embryonic lethal. Altogether, these observations sugges-
ted that the expression of U6-Fgfr2 RNAi might result in
severe developmental defects, leading to embryonic lethality
of majority of mutant mice. To conﬁrm this, we crossed the
U6-ploxPneo-Fgfr2 mice (Line A) with EIIa-Cre mice and
dissected females at days 11.5 through 13.5 during their preg-
nancy. Our data indicated that U6-Fgfr2;EIIa-Cre embryos
were present at a Mendelian ratio (Table 1, crosses between
U6-ploxPneo-Fgfr2 and EIIa-Cre mice). However,  60%
(8/14) of them were developmentally abnormal or partially
resorbed (Figure 1Dand E), while no obvious differences were
found among control (wild type, EIIa-Cre or U6-ploxPneo-
Fgfr2) embryos in the same litters.
Our previous study performed in ES cells indicated that
Cre-mediated deletion of the ploxPneo restored the original
distance between the distal sequence element and the proximal
sequence element in the U6 promoter. It allowed the expres-
sion of Fgfr2 RNAi, and, consequently, led to a markedly
reduction of Fgfr2 transcripts (3). To determine whether
this occurred in vivo, we performed the following three experi-
ments using Line A transgenic mice: we ﬁrst determined the
number of copies of the U6-ploxPneo-Fgfr2 transgene by real-
time PCR. Our analysis using a pair of primers located in
the neo gene indicated that the transgenic mice contained
ﬁve copies of the transgene (Figure 2A). This analysis also
revealed that the intensity of the neo decreased to  20% in
U6-Fgfr2;EIIa-Cre embryos compared with the embryos
without Cre (Figure 2A). The similar decrease of neo intensity
was also revealed by genomic PCR analysis using primers
against the neo (Figure 2B). To conﬁrm that this reduction
is caused by neo deletion, we performed PCR using primers
ﬂanking the ploxPneo. Our analysis detected Cre-mediated
deletion (del) product in DNA isolated from U6-Fgfr2;
Table 1. Offspring and genotypes of crosses between U6-ploxPneo-Fgfr2 mice (Line A) with EIIa-Cre or AP2-Cre transgenic mice
Ages Total WT EIIa-Cre U6-ploxPneo-Fgfr2 U6-Fgfr2;EIIa-Cre AP2-Cre U6-Fgfr2;AP-2Cre
Crosses between U6-ploxPneo-Fgfr2 and EIIa-Cre mice
After birth 81 27 25 27 2
a
E11.5–E13.5 51 10 10 17 14
Crosses between U6-ploxPneo-Fgfr2 and AP2-Cre mice
After birth 62 21 10 15 16
b
aSmall size and limb abnormalities.
bAll displayed limb defects.
Figure 2. Cre-mediateddeletionoftheneofromU6-ploxPneo-Fgfr2transgeneallowsexpressionofFgfr2RNAi.(A)AssessmentofcopynumberofU6-ploxPneo-
Fgfr2 transgene by real-time PCR using primers for neo gene. DNA extracted from Sirt6+/  and Fgfr1 /  ES cells are used as controls for 1 copy and 2 copies of
neo gene, respectively. Primers for Fgfr1 genomic DNA are used as analysis control. (B) Assessment of neo gene deletion by genomic PCR using primers for
ploxPneo (neo) and primers that flanking the neo. PCR using neo primers is stopped at 25 cycles and all others are stopped at 30 cycles. (C) Northern blot analysis
showingthatU6-Fgfr2transgeneisonlyexpressedinU6-Fgfr2;EIIa-Cremice.EqualRNAloadingwasassessedbyethidiumbromidestainingoftheupperportion
of the gel (lower). All samples, except for those from ES cells, are from E12.5 embryos.
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other genotypes (Figure 2B). Then, we performed northern
blot analysis using RNAs extracted from U6-Fgfr2;
EIIa-Cre, wild type and U6-ploxPneo-Fgfr2 whole embryos.
Our analysis detected a strong band of predicted size of 86 nt
(63 bases for the two RNAi oligos and hairpin sequences and
23 bases from transcription initiation site to the beginning of
the ﬁrst oligo) in U6-Fgfr2;EIIa-Cre, but not in wild-type
and U6-ploxPneo-Fgfr2 embryos (Figure 2C). These data
provide in vivo evidence that the presence of the neo gene
efﬁciently silenced the U6 promoter and its deletion restored
the promoter activity.
Next, we determined if the expression of Fgfr2 RNAi could
efﬁciently knockdown Fgfr2 in vivo using RT–PCR. Our data
revealed a dramatic (>95%) down-regulation of Fgfr2 mRNA
levels in all three E12.5 U6-Fgfr2;EIIa-Cre embryos
examined, while no obvious alteration was observed in U6-
ploxPneo-Fgfr2 and EIIa-Cre embryos compared with their
wild-type littermates (Figure 3A). Fgf receptors exist as a gene
family of four members. Our analysis revealed that U6-Fgfr2
RNAi-mediated suppression is speciﬁc to Fgfr2, but not other
members (Figure 3A). Finally, our real-time PCR analysis
conﬁrmed dramatic down-regulation of Fgfr2 transcripts in
the U6-Fgfr2;EIIa-Cre, but not in any other control embryos
(Figure 3B). These observations provide a molecular basis
for the observed embryonic lethality of U6-Fgfr2;EIIa-Cre
embryos.
Limb distal mesenchyme-specific knockdown of
Fgfr2 results in abnormal digit formation
Thus, we have created a Cre-mediated conditional Fgfr2
mutant strain using the RNAi technology. This strain of
mice should be a useful tool for studying functions of Fgfr2
in the development and formation of multiple organs/tissues.
To demonstrate this in principle, we performed limb-speciﬁc
knockdown of Fgfr2 by crossing the U6-ploxPneo-Fgfr2 mice
with AP2-Cre transgenic mice, which express Cre in the distal
mesenchyme [also called progress zone (27)] right after limb
bud initiation (25). After crossing with the two strains, we
observed a normal distribution of double transgenic animals
(U6-Fgfr2;AP2-Cre) at birth (Table 1, crosses between
U6-ploxPneo-Fgfr2 and AP2-Cre mice). However, all the
U6-Fgfr2;AP2-Cre animals exhibited limb abnormalities
characterized by the reduced number of digits in both the
forelimbs(Figure4A)andhindlimbs(Figure4B).Alizarinred-
and alcian blue-stained whole-mount skeleton imaging
revealed that all mutant forelimbs only had two relatively
normal digits (digits 4 and 5), while the anterior digits were
either missing or developmentally retarded (Figure 4C) in
comparison with controls (Figure 4D). On the other hand, all
the mutant hindlimbs did not have the third digit (Figure 4E,
arrow), while other digits present, however, appeared abnor-
mal (Figure 4F). Furthermore, mutant hindlimbs showed
delayed ossiﬁcation of tarsal bones and distortion in the ankles
(Figure 4E and F). In contrast, all control animals (wild
type, U6-ploxPneo-Fgfr2 and AP2-Cre) appeared normal
(Figure 4C and D). Collectively, these results demonstrate
that RNAi can be used to achieve spatial and temporal knock-
down of transcripts in mouse.
DISCUSSION
The 3 · 10
9 base sequence of mouse genome encodes at least
30000 genes. Despite great efforts having been directed at
deciphering functions of these genes by gene targeting, pub-
lished knockouts represent only  10% of mouse genes (28).
One of the obvious rate limiting factors is the generation of
mutant mice, especially those carrying conditional mutations,
which requires multi-step modiﬁcations (29). In this paper,
we have described a method that can be used for conditional
RNAi in vivo on endogenous genes, using the widely used
Cre-LoxP system (15). We showed that the expression of
U6-Fgfr2 RNAi in mouse germline suppressed Fgfr2 expres-
sion with high efﬁciency, as only <5% of Fgfr2 transcripts
were detected compared with those of controls. We have also
performed progress-zone-speciﬁc knockdown of Fgfr2 and
demonstrated, in principle, that our strategy can be applied
for tissue-speciﬁc targeted gene suppression. Given the critical
roles of Fgfr2 in mammalian development (17), the U6-
ploxPneo-Fgfr2 mice should be useful in assessing functions
of this gene in multiple organs/tissues. We are in the process
to cross this strain with transgenic mice that express Cre in a
number of other tissues. Because the ratio of RNAi to targeted
mRNA varies from one cell type to another, the efﬁciency of
Figure 3. Analysis of Fgfr1-4 expression. (A) RT–PCR analysis of Fgfr1-4
expression in E12.5 embryos of different genotypes. Wt, wild type; U6,
U6-ploxPneo-Fgfr2; Cre, EIIa-Cre; and U6;Cre, U6-Fgfr2;EIIa-Cre. The first
rowisalongerexposureofthesecondrow.(B)Real-timePCRanalysisofFgfr2
mRNAlevels.Threeembryosforeachgenotypewereshown.Thethreemutant
embryos used here were less affected and had similar size compared with the
littermate controls. The experiments were repeated at least three times and
similar data were obtained on each time.
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efﬁciency of Fgfr2 knockdown in different tissues.
Because our approach does not require constructing
sophisticated gene-targeting vectors and ES cell manipulation,
it is relatively fast to generate mutant mice carrying
RNAi construct. In this study, we were able to generate the
U6-ploxPneo-Fgfr2 mice in 3 months, a signiﬁcant gain of
time compared with homologous recombination procedures
forthe conditional gene knockouts(12–24 months).Moreover,
because RNAi acts dominantly, only one allele of transgene is
needed to suppress the endogenous genes, and it reduces the
time needed for breeding together two mutant alleles required
by conditional knockout of genes with recessive nature. This
advantage becomes more obvious when genetic interaction of
two or more genes is studied (30,31). Thus, compared with the
gene targeting technique, our approach is both fast and simple,
and therefore should be widely accessible.
In our approach, U6-ploxPneo-Fgfr2 construct was intro-
duced through pronuclear injection to obtain mutant mice.
Although our crosses between all three U6-ploxPneo-Fgfr2
founder strains with EIIa-Cre transgenic mice resulted in sim-
ilar embryonic lethality, the expression of transgenes, in the-
ory, should subject to position effects. This is primarily caused
by random integration of transgenes into different chromo-
somal sites that differentially regulate gene expression (32).
Thus, the activity of U6 promoter may vary at different integ-
ration sites. Apparently, position independent and high levels
of gene expression are essential for the success of our
approach. It is reported recently that position effect can be
minimized or overcome by using an insulator (33). This is a
promising strategy that should be tested in the next generation
of the RNAi constructs.
We found that the U6-Fgfr2;EIIa-Cre animals died at
different stages of embryonic development and two mutant
Figure 4. Abnormal digit formation and limb development in U6-Fgfr2;Ap-2Cre mice. (A and B)P 7U6-Fgfr2;Ap-2Cre and control forelimbs (A) and hindlimbs
(B).(C–F)Alizarinred-andalcian-bluestainedU6-Fgfr2;Ap-2Cre(CandE)andcontrol(DandF)limbs.(CandD)wereforelimbs,and(EandF)werehindlimbs.
Arrow in (E) points to the third finger, which is truncated in all mutant limbs. Arrow in (F) points to calcified tarsal bones, which have not developed in mutant
bones (E). Note, the tibia and fibula of mutant hindlimbs (E) were out of focus because of a distortion in the ankle. Ra, radius; Ul, ulna; Ti, tibia; Fi, fibula.
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U6-ploxPneo-Fgfr2 and EIIa-Cre mice). Because all these
mice were derived from a single transgenic founder line,
this variation was not due to the position effects on the trans-
gene. Instead, it could be due to the fact that each animal
contained varying degree of Fgfr2 knockdown level, with
most severe knockdown leading to earlier lethality. One of
the factors that may affect the efﬁciency of Fgfr2 knockdown
is the extent of ploxPneo deletion. Based on our experience
on conditional knockout of a number of genes, Cre-mediated
deletion of ﬂoxed sequences is in a range of 60–90% and
never reaches 100% even in the most efﬁcient case (31,34).
Our real-time PCR analysis indicated that the efﬁciency of the
ploxPneo deletion by EIIa-Cre is  80%, which is comparable
with efﬁciencies of most conditional knockouts. Another fac-
tor that may affect Creefﬁciency isthe copy numberofloxP. It
was shown previously that EIIa-Cre could cause incomplete
deletion of DNA sequences containing three loxP sites and
create mosaicism (35,36). Thus, efﬁciency of Cre may be
further reduced in situations when many copies of transgene
were cumulated at one locus. In this case, weak Cre activity
may result in a variable number of active transgene while in
case of strong Cre, only one active transgene will be left. This
could result in an additional level of phenotypic variation. One
way to avoid high copy number of the transgene is to reduce
concentration of DNA for pronuclear injection. Furthermore,
phenotypic variation could also occur if the RNAi transgenic
mice used for the crossing with Cre-transgenic mice still car-
ried more than one transgene integration that had not yet
segregated from each other. Although the integration of trans-
gene into multiple loci is uncommon, it needs to take into
account. One way to overcome this is to breed the transgenic
mice with wild-type for a number of generations before cross-
ing them with Cre transgenic mice. However, this may be both
time and labor consuming. In this study, instead of using
wild-type mice, we directly crossed F1 with EIIa-Cre mice,
as this cross should generate one-fourth of U6-ploxPneo-Fgfr2
transgenic mice (F2), which were further crossed with EIIa-
Cre mice to generate F3, then F4 and so on. At the same time,
these crosses should also generate one-fourth of U6-Fgfr2;
EIIa-Cre mice at each generation that can be used for pheno-
typic analysis. During the course of this work, some U6-
Fgfr2;EIIa-Cre mice have reached more than seven genera-
tions and they still showed same phenotype compared with
earlier generations.
On the other hand, phenotype variation is often observed in
mice generated by gene targeting, suggesting that it is an
intrinsic feature associated with the loss of function mutation,
perhaps due to a difference response of each individual to the
mutation. Actually, this could be beneﬁcial in some circum-
stances where variable phenotypes associated with some
knockouts may reveal new and unexpected information.
Thus, scientists intentionally generate hypomorphic alleles
using sophisticated targeting modiﬁcations (37). This is a
challenge for RNAi after minimizing the undesired position
effects; however, it may be achieved in two ways: one is the
actual copy number of the RNAi transgene (i.e. breeding
of heterozygote to homozygote), and the other is using a
suboptimal shRNA vector, asvarying efﬁciencyalways occurs
in culture cells when different sequences of the same gene
are used.
During the course of this study, two recent investigations
showed that lentivirus-based RNAi systems could be used
to generate transgenic animals with Cre-loxP mediated gene
knockdown (38,39). While it is not possible to have a direct
comparison between different approaches, our work is the ﬁrst
demonstration that the plasmid-based RNAi, with its simpli-
city in construction, can be used to speciﬁcally knockdown an
endogenous gene, Fgfr2, with high efﬁciency in vivo. Because
all the techniques using RNAi to suppress endogenous genes
are still in their early developing stages, our method should
provide an additional choice for this scientiﬁc ﬁeld.
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